|Articles|January 1, 2001

January 2001
Volume 7
Issue 1

Indirect Cost of Ischemic Heart Disease to Employers

Author(s)Christine J. Guico-Pabia, MD, MBA, James F. Murray, PhD, Steven M. Teutsch, MD, MPH

Download PDF: Indirect Cost of Ischemic Heart Disease to Employers

Articles in this issue

over 25 years ago

Article

Disenrollment from Medicare HMOs

over 25 years ago

Article

A Comparison of Abciximab Use in MCO and Non-MCO Populations

over 25 years ago

Article

Drugs and the Elderly, Part 2: Strategies for Improving Prescribing in a Managed Care Environment

over 25 years ago

Article

Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug Use

over 25 years ago

Article

The Employer's Perspective

over 25 years ago

Article

Can Administrative Database Studies Inform Medication Use Policy Decisions? An Application of Occam's Razor

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Indirect Cost of Ischemic Heart Disease to Employers

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs

MS Likely Unfolds Along a Continuum Years Before First Symptoms

Innovation Is Outpacing Reimbursement, Health System Execs Warn